Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Will Biogen (BIIB) Beat Estimates This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Sage and Biogen's NDA for Depression Drug Gets Priority Review
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
by Zacks Equity Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
This "Golden" Technical Indicator is Triggering Across the Market
by Andrew Rocco
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
by Zacks Equity Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
by Zacks Equity Research
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.
Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.
Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma
by Zacks Equity Research
Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day.